Saliva
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA983278 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR24976934_1.fastq.gz | Fastqsanger.gz | |||
| SRR24976934_2.fastq.gz | Fastqsanger.gz | |||
| SRR24976935_1.fastq.gz | Fastqsanger.gz | |||
| SRR24976935_2.fastq.gz | Fastqsanger.gz | |||
| SRR24976936_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 108 |
Similar Datasets
Project description:Background: The microbiome is increasingly being linked to cancer risk. Little is known about the lung and oral cavity microbiomes in healthy smokers (SM), and even less for electronic cigarette (EC) users, compared healthy never-smokers (NS). Methods: In a cross-sectional pilot study of SM (N=8), EC users (N=10) and NS (N=10) saliva and bronchoscopy-collected bronchoalveolar lavage samples were collected. Bacteria species were identified through metatranscriptome profiling by RNA-sequencing to study associations with the lung and oral microbiome. Pairwise comparisons and linear modeling was assessed with false discovery rates <0.1. Results: Total bacterial load was similar for the SM, EC users and NS, and there was no differences in the bacterial diversity across groups. In the lung, there were 44 bacterial species that were statistically significantly different for SM/NS, 80% of which were decreased in the SM. There were 12 bacterial species that were different for SM/EC users, all of which were decreased, 10 of which were also identified in the SM/NS comparison. The 2 bacterial species unique to SM/EC comparison were Neisseria sp. KEM232 and Curvibacter sp. AEP1-3. From the top 5 decreased species in SM/EC, 3 were also identified in the SM/NS comparison (Neisseria elongata, Neisseria sicca, and Haemophilus parainfluenzae) and 2 of these were unique to the SM/EC comparison (Neisseria zoodegmatis and Ottowia sp. oral taxon 894). There were 8 species increased in SM compared to NS, none of which are known to be clinically significant. In the oral microbiome, 152 bacteria species were differentially abundant for the SM/NS analysis, and only 17 for the EC/NS comparison, all which were also present in SM/NS comparisons. There were 21 bacteria that were differentially abundant in both the lung and oral cavity for SM and NS, 95% also were decreased in the SM. Conclusion: Smoking and EC use do not appear to materially affect the lung microbiome, although differences are noted of unclear clinical significance. Most differentially abundant bacteria decreased, which may be due to a toxic effect of cigarette smoke, including a change in humidity or heating. Given the low number of overlapping oral and lung microbes, the oral microbiome does not appear to be a good surrogate for smoking-related effects in the lung.
2022-07-13 | GSE180785 | GEO
Project description:16srRNA sequences of bacteria in saliva, Study of oral microbiome in Dental Disease Patients and Oral Healthy Patients
| PRJDB14943 | ENA
Project description:In this paper, we first report that EC smoking significantly increases the odds of gingival inflammation. Then, we seek to identify and explain the mechanism that underlies the relationship between EC smoking and gingival inflammation via the oral microbiome. We performed mediation analyses to assess if EC smoking affects the oral microbiome, which in turn affects gingival inflammation. For this, we collected saliva and subgingival samples from EC users and non-users and profiled their microbial compositions via 16S rRNA amplicon sequencing. We then performed α-diversity, β-diversity, and taxonomic differential analyses to survey the disparity in microbial composition between EC users and non-users. We found significant increases in α-diversity in EC users and disparities in β-diversity between EC users and non-users.
2022-12-09 | GSE201949 | GEO
Project description:Relationship between oral frailty and saliva microbiome
| PRJNA940274 | ENA
Project description:Variations in the susceptibility to SARS-CoV-2 infection and risk of severe disease are yet not well understood. The information on the human pathways and active members of the microbiome that can affect SARS-CoV-2 susceptibility and disease progression in the saliva is very scarce. Here, we studied 10 hospitalized patients with severe and moderate COVID-19 (Scov and Mcov) at an early stage of the disease during April to June 2020, compared to 10 uninfected individuals, including healthcare workers with repeated high-risk exposures to the virus but not infected (Non-susceptible, Nsus) and subjects who became infected during the follow-up (susceptible, Non-COVID, Ncov). We performed high-throughput proteomic profiling in saliva to determine the human pathways and active members of the microbiome across individuals. We detected differentially expressed proteins between groups, being the differences especially remarkable in the comparison between the non-infected vs the non-susceptible groups. In a functional analysis to correlate the putative protein biomarkers with relevant biological functions, we found increased expression of proteins related to inflammatory responses and central cellular processes and decreased expression of molecules involved in antiviral activity. The most noteworthy are the Cystatin family, protective molecules present at the oral cavity, the Calprotectin family involved in cell cycle progression, or the Histone family related to nucleosome functions. Furthermore, since proteomics allows checking microbiome functionality, we explored bacterial products and found in the COVID-19+ group 4 overrepresented genera and 2 phyla together with 4 main functional features (KOs) related to ribosomal proteins. Finally, we studied correlations with the plasma activity of the molecular target of SARS-CoV-2, ACE2, and found a link with two proteins related to protein transport through the microtubules in the cytoplasm (DYBC1 and MAPR1). Our study delineates new mechanisms of SARS-CoV-2 susceptibility and progression to severe disease that may help find better therapies for COVID-19.
2024-05-31 | PXD032333 | Pride
Project description:Alterations in the oral microbiome of methamphetamine addicts
| PRJNA970411 | ENA
Project description:Aging is associated with declining immunity and inflammation as well as alterations in the gut microbiome with a decrease of beneficial microbes and increase in pathogenic ones. The aim of this study was to investigate aging associated gut microbiome in relation to immunologic and metabolic profile in a non-human primate (NHP) model. 12 old (age>18 years) and 4 young (age 3-6 years) Rhesus macaques were included in this study. Immune cell subsets were characterized in PBMC by flow cytometry and plasma cytokines levels were determined by bead based multiplex cytokine analysis. Stool samples were collected by ileal loop and investigated for microbiome analysis by shotgun metagenomics. Serum, gut microbial lysate and microbe-free fecal extract were subjected to metabolomic analysis by mass-spectrometry. Our results showed that the old animals exhibited higher inflammatory biomarkers in plasma and lower CD4 T cells with altered distribution of naïve and memory T cell maturation subsets. The gut microbiome in old animals had higher abundance of Archaeal and Proteobacterial species and lower Firmicutes than the young. Significant enrichment of metabolites that contribute to inflammatory and cytotoxic pathways was observed in serum and feces of old animals compared to the young. We conclude that aging NHP undergo immunosenescence and age associated alterations in the gut microbiome that has a distinct metabolic profile.
2022-02-01 | E-MTAB-10160 | biostudies-arrayexpress
Project description:HuMiChip was used to analyze human oral and gut microbiomes, showing significantly different functional gene profiles between oral and gut microbiome. The results were used to demonstarte the usefulness of applying HuMiChip to human microbiome studies.
2014-02-04 | E-GEOD-54290 | biostudies-arrayexpress